Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade) (NASDAQ:NTLA)

Intellia Therapeutics, Inc.'s gene-editing therapies show strong potential with robust efficacy, safety, and market demand. Click for my NTLA earnings update.